Understanding the Setup: (ATEC) and Scalable Risk
This article analyzes Alphatec Holdings Inc. (NASDAQ: ATEC) using AI models to provide trading strategies and risk parameters. It notes weak near and mid-term sentiment but a strong long-term outlook, with elevated downside risk due to a lack of additional long-term support signals. The analysis includes position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
Alphatec (ATEC) to Release Earnings on Tuesday
Alphatec (NASDAQ:ATEC) is scheduled to release its Q4 2025 earnings after the market closes on Tuesday, February 24th, with analysts projecting earnings of $0.04 per share and revenue of $212.67 million. Insiders have been net sellers in recent months, disposing of over 2.2 million shares, though they still retain 22.8% ownership. The stock currently has a "Moderate Buy" rating from analysts with a consensus price target of $22.82.
Alphatec Holdings, Inc. (ATEC) Stock Analysis: High Growth and 82% Potential Upside for Savvy Investors
Alphatec Holdings, Inc. (ATEC) is a medical device company specializing in spinal disorder solutions, showing 30.40% revenue growth despite negative EPS and ROE, indicating a focus on innovation reinvestment. Analysts project an 82.20% upside with a consensus target price of $24.62, although its current trading below moving averages and high P/E ratio suggest volatility and risk. Savvy investors might consider its growth potential, weighing it against high valuation and profitability challenges.
Alphatec Holdings stock hits 52-week high at $13.84
Alphatec Holdings stock (ATEC) recently approached $13.75, showing recovery from its 52-week low but remaining below its actual 52-week high. Despite strong revenue growth and analyst optimism for future profitability, the stock is considered overvalued with a significant year-to-date decline. Recent Q4 2025 results exceeded revenue expectations, but growth deceleration and 2026 guidance, while above consensus, led to a nearly 20% stock plunge due to lower growth rates compared to historical performance.
The Technical Signals Behind (ATEC) That Institutions Follow
This article analyzes the technical signals for Alphatec Holdings Inc. (NASDAQ: ATEC) as of February 8, 2026. It identifies weak near and mid-term sentiment, potentially challenging a long-term positive outlook, and points out elevated downside risk without additional long-term support signals. The article also provides AI-generated institutional trading strategies for various risk profiles, including long, breakout, and short positions, along with multi-timeframe signal analysis.
Alphatec Holdings EVP Sponsel sells $833k in stock
Alphatec Holdings Executive Vice President of Sales, David Sponsel, sold 60,425 shares of the company's common stock for approximately $833,260 on February 5, 2026. The sale occurred under a pre-arranged 10b5-1 trading plan, with shares trading at a weighted average price of $13.79. Despite a 34% year-to-date decline in stock price, Alphatec (NASDAQ:ATEC) showed strong revenue growth and is expected to achieve profitability this year.
Alphatec Holdings EVP Sponsel sells $833k in stock By Investing.com
David Sponsel, EVP of Sales at Alphatec Holdings, sold 60,425 shares of common stock for $833,260 on February 5, 2026, under a pre-arranged trading plan. Despite the company's strong revenue growth, its stock has declined 34% year-to-date, though it is trading near its Fair Value with analysts forecasting profitability this year. Alphatec is set to report earnings on February 24, following preliminary Q4 and full-year 2025 results that exceeded expectations but included 2026 revenue guidance that concerned investors.
Alphatec Holdings EVP Hunsaker sells $549k in stock
Craig E Hunsaker, EVP of People & Culture at Alphatec Holdings (NASDAQ:ATEC), sold 37,358 shares worth approximately $549,536 on February 3, 2026, under a pre-arranged trading plan to cover tax obligations. Despite the company not currently being profitable, analysts project profitability for the current year, with strong revenue growth and the stock trading near its InvestingPro Fair Value. Recent company news includes Q4 and full-year 2025 results that exceeded expectations and a 17% revenue growth forecast for 2026, although the stock experienced a significant decline post-announcement.
Alphatec Holdings EVP Hunsaker sells $549k in stock By Investing.com
Alphatec Holdings Executive Vice President, Craig E Hunsaker, sold 37,358 shares of common stock for approximately $549,536 on February 3, 2026, under a pre-arranged Rule 10b5-1 trading plan to cover tax obligations. Despite the company's current unprofitability, analysts project profitability for the current year, and Alphatec reported strong revenue growth and exceeded preliminary fourth-quarter and full-year 2025 expectations.
Alphatec Holdings EVP Hunsaker sells $549k in stock By Investing.com
Alphatec Holdings Executive Vice President, Craig E Hunsaker, sold 37,358 shares of common stock for approximately $549,536 to cover tax obligations. Despite the company not currently being profitable, analysts predict profitability this year, with strong revenue growth and trading near its InvestingPro Fair Value. Alphatec also reported preliminary Q4 and full-year 2025 results that exceeded expectations and forecasted 17% revenue growth for 2026.
Alphatec Holdings EVP Hunsaker sells $549k in stock
Alphatec Holdings' EVP, Craig E. Hunsaker, sold 37,358 shares for approximately $549,536 under a pre-arranged trading plan to cover tax obligations. Despite the company not currently being profitable, analysts predict profitability this year, and it has shown strong revenue growth. These sales follow a recent decline in Alphatec's stock after its Q4 and full-year 2025 preliminary results, even though they modestly exceeded expectations.
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Viridian Therapeutics (VRDN) and Enovis (ENOV)
Three analysts have issued bullish sentiments on healthcare companies Alphatec Holdings (ATEC), Viridian Therapeutics (VRDN), and Enovis (ENOV). Canaccord Genuity maintained a Buy rating on Alphatec Holdings with a $25 price target, and also on Enovis with a $50 price target. Wedbush maintained a Buy rating on Viridian Therapeutics with a $47 price target.
Here's Why Alphatec Holdings (NASDAQ:ATEC) Can Afford Some Debt
Alphatec Holdings (NASDAQ:ATEC) carries debt, with US$559.7m reported at the end of September 2025, offset by US$155.7m in cash, resulting in a net debt of US$403.9m. Despite current liabilities exceeding short-term assets by US$495.8m, the company's US$2.21 billion market cap suggests it could raise capital if needed. However, concerns are raised due to an EBIT loss of US$74m and negative free cash flow of US$3.4m, indicating a potentially risky balance sheet that could improve over time with profitability.
227,287 Shares in Alphatec Holdings, Inc. $ATEC Bought by Lisanti Capital Growth LLC
Lisanti Capital Growth LLC has acquired 227,287 shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) worth approximately $3.31 million, establishing a new position in the company. While institutional investors are increasing their stake, insiders have been net sellers, offloading over 3.2 million shares in the past 90 days. Alphatec holds a "Moderate Buy" consensus rating from analysts with an average target price of $22.82, and recently exceeded EPS and revenue estimates.
Y Intercept Hong Kong Ltd Acquires Shares of 116,106 Alphatec Holdings, Inc. $ATEC
Y Intercept Hong Kong Ltd has acquired 116,106 shares of Alphatec Holdings, Inc. (NASDAQ:ATEC), a medical technology company, valued at approximately $1.69 million, establishing a new position representing about 0.08% of the company. Despite recent insider selling, institutional investors have also been modifying their holdings. Analysts maintain a "Moderate Buy" rating for Alphatec, with an average target price of $22.82.
TD Cowen Maintains Buy Rating for Alphatec (ATEC) While Adjusting PT to $20 Following Coverage Transfer
TD Cowen has reiterated its Buy rating for Alphatec (ATEC) but adjusted its price target to $20 from $27 after a coverage transfer. The firm believes the market currently undervalues Alphatec's growth prospects, including its 2026 revenue outlook of $890 million and the acquisition of exclusive US rights to Theradaptive’s OsteoAdapt bone graft. This undervaluation, along with recent strategic partnerships like the one for OsteoAdapt, suggests potential for upward revisions in financial estimates as Alphatec advances its spine medtech strategy.
11 Best High Short Interest Stocks With Biggest Upside Potential
Alphatec Holdings Inc. (NASDAQ: ATEC) is highlighted as a high short interest stock with significant upside potential, supported by 40 hedge funds. TD Cowen maintained a buy rating, despite lowering its price target to $20, citing undervaluation of the company's growth vectors, including its 2026 revenue outlook and the exclusive US rights acquisition for OsteoAdapt, a bone graft for spinal fusion. This partnership aims to disrupt the $10 billion US spine biologics market.
ATEC Stock Price, Forecast & Analysis | ALPHATEC HOLDINGS INC (NASDAQ:ATEC)
This article provides an analysis of Alphatec Holdings Inc. (NASDAQ: ATEC), including its stock price, technical and fundamental ratings, and analyst forecasts. As of the last trading session, ATEC's stock price was $15.62, having decreased by 25.62% in the past month but increased by 41.87% in the past year. Analysts project an average price target of $25.42, implying a 62.75% increase in the next year.
What Alphatec Holdings (ATEC)'s Exclusive OsteoAdapt Rights Mean For Shareholders
Alphatec Holdings (ATEC) secured exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt, a regenerative bone graft for spinal fusion, integrating it into Alphatec's growing spine surgery ecosystem. This partnership could reshape Alphatec's role in the over $10 billion U.S. spine surgery market, aligning with its strategy to convert procedure growth into improved economics despite current unprofitability. The firm's investment narrative projects $1.1 billion in revenue and $93.9 million in earnings by 2028, with a fair value estimate of $24.62, though investors also weigh the risk of prolonged cash burn against this upside potential.
What Alphatec Holdings (ATEC)'s Exclusive OsteoAdapt Rights Mean For Shareholders
Alphatec Holdings (ATEC) secured exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt, an FDA Breakthrough-designated bone graft for spinal fusion. This partnership aims to strengthen Alphatec's position in the over $10 billion U.S. spine surgery market, aligning with its strategy to grow its spine-focused ecosystem. While the deal deepens Alphatec’s biologics offering, success hinges on achieving its 2026 revenue target and managing sustained cash burn from R&D investments.
Alphatec (ATEC) jumps 9.5% on bargain-hunting after 2-month low
Alphatec Holdings Inc. (ATEC) stock increased by 9.5% today, closing at $11.83 after reaching a two-month low of $10.8 yesterday. This rise is attributed to bargain-hunting by investors following a significant 34.6% decline over the past two months. The company's recent strong Q3 FY23 results, which exceeded revenue and earnings estimates, support this positive sentiment despite the stock's previous downturn.
SG Americas Securities LLC Makes New Investment in Alphatec Holdings, Inc. $ATEC
SG Americas Securities LLC has made a new investment in Alphatec Holdings, Inc. (NASDAQ:ATEC), acquiring 76,659 shares valued at approximately $1.115 million. Alphatec reported strong Q3 earnings, beating analyst estimates with EPS of $0.03 and revenues up 30.4% year-over-year. Despite recent insider selling, institutional investors hold a significant portion of the stock, and analysts maintain a "Moderate Buy" rating with an average target price of $22.82.
Alphatec (ATEC) Jumps 9.5% on Bargain-Hunting After 2-Month Low
Alphatec Holdings Inc. (ATEC) saw a 9.5% increase in its stock price, closing at $17.46, after falling to a two-month low. This surge was attributed to bargain-hunting by investors following the preliminary release of its 2025 earnings, which indicate total revenues between $763.4 million and $764.4 million, exceeding previous guidance. The company also projects strong growth for 2026, targeting $890 million in revenues.
Alphatec Holdings, Inc. (ATEC) Shares Preliminary 2025 Results and 2026 Outlook
Alphatec Holdings, Inc. (ATEC) announced strong preliminary 2025 financial results, with total revenue increasing 25% to $763.4-$764.4 million, driven by a 26% surge in surgical revenue. The company also provided an optimistic 2026 outlook, projecting $890 million in revenue and $130 million in adjusted EBITDA, alongside a strategic agreement to acquire exclusive distribution rights for Theradaptive’s OsteoAdapt. Analysts are bullish, with Needham and HC Wainwright & Co. reiterating Buy ratings and a consensus average price target of $24.55.
Alphatec Holdings, Inc. (ATEC) Shares Preliminary 2025 Results and 2026 Outlook
Alphatec Holdings, Inc. (ATEC) announced preliminary 2025 financial results, with total revenue increasing 25% to between $763.4 million and $764.4 million, and reaffirmed adjusted EBITDA guidance of $91 million. For fiscal 2026, the company projects $890 million in revenue, $130 million in adjusted EBITDA, and $20 million in free cash flow. Additionally, ATEC entered a strategic agreement with Theradaptive for exclusive U.S. distribution rights of OsteoAdapt, leading to reiterated "Buy" ratings from analysts.
A Look At Alphatec Holdings (ATEC) Valuation After 2026 Guidance Update And Theradaptive OsteoAdapt Deal
Alphatec Holdings (ATEC) recently saw its stock decline following a 2026 revenue guidance update implying slower growth, despite securing exclusive U.S. rights to Theradaptive’s OsteoAdapt bone graft. While the company has a 47.9% one-year total shareholder return, its short-term momentum has faded. The article discusses whether the current pullback offers a mispriced entry, noting that a common valuation narrative suggests Alphatec is 33.2% undervalued with a fair value of US$24.62 per share, driven by innovation in surgical solutions.
Alphatec Holdings (ATEC) Is Down 27.4% After Issuing 2026 Revenue Guidance And OsteoAdapt Deal
Alphatec Holdings (ATEC) saw its stock drop 27.4% after announcing a partnership with Theradaptive for exclusive U.S. commercialization rights to OsteoAdapt, an osteoinductive bone graft, and issuing 2026 revenue guidance of approximately US$890 million. This guidance implies a slower projected growth rate of about 17% compared to 2025, leading investors to re-evaluate the company's investment narrative, focusing on balancing growth with disciplined spending and improving margins. The article emphasizes that execution on margin improvement and cash burn will be crucial for Alphatec's near-term performance.
Alphatec Holdings (ATEC) Gets a Buy from Wells Fargo
Wells Fargo analyst Vik Chopra maintained a Buy rating on Alphatec Holdings (ATEC) with a $28.00 price target. This recommendation follows Alphatec Holdings' latest quarterly revenue of $196.5 million, an increase from the previous year, despite a continued GAAP net loss. While Canaccord Genuity also issued a Buy rating, Stifel Nicolaus maintained a Hold rating, and corporate insider sentiment for the stock is currently negative due to increased insider selling.
Latham Advises Theradaptive on Strategic Partnership with ATEC
Latham & Watkins advised Theradaptive, Inc. on its strategic partnership with Alphatec Holdings, Inc. (ATEC). This agreement grants ATEC exclusive U.S. commercial rights to market and distribute Theradaptive's OsteoAdapt® osteoinductive bone graft for spinal fusion. The Latham team was led by London counsel Oliver Mobasser.
Alphatec Touts 2026 Growth Plan at JPMorgan Conference, Guides to $890M Revenue and $20M FCF
Alphatec (NASDAQ:ATEC) presented its 2026 growth strategy at a JPMorgan healthcare conference, projecting $890 million in revenue (+17%), $130 million in adjusted EBITDA, and $20 million in free cash flow. The company emphasized "proceduralization" and informatics as key growth drivers, integrating various technologies like SafeOp, EOS imaging, and the upcoming Valence navigation system. Alphatec also reaffirmed its long-term goal of achieving $1 billion in revenue and $180 million in adjusted EBITDA by 2027.
Does Alphatec (ATEC) Pairing With OsteoAdapt Quietly Redraw Its Spine Biologics Investment Narrative?
Alphatec Holdings, Inc. recently partnered with Theradaptive, securing exclusive U.S. rights to commercialize the OsteoAdapt osteoinductive bone graft for spinal fusion. This collaboration, along with strong preliminary 2025 results and 2026 revenue guidance of approximately US$890 million, could reshape Alphatec's investment narrative in spine biologics. While OsteoAdapt holds significant potential, it is still in clinical trials, meaning Alphatec's near-term growth remains dependent on its existing hardware, navigation, and robotics portfolio.
Alphatec Holdings Inc (ATEC) Shares Gap Down to $16.58 on Jan 13
Alphatec Holdings Inc (ATEC) shares dropped 5.74% on January 13, reaching an intraday low of $16.50 before closing at $16.58. This places the stock 28.81% below its 52-week high but 88.20% above its 52-week low. Wall Street analysts forecast an average target price of $24.62, suggesting a 48.46% upside, and GuruFocus estimates a one-year GF Value of $18.93, indicating a 14.17% upside.
New spinal fusion bone graft pairs Alphatec with Theradaptive
Alphatec Holdings (ATEC) has entered a strategic partnership with Theradaptive on January 12, 2026, securing exclusive U.S. commercial rights to Theradaptive's OsteoAdapt osteoinductive bone graft for spinal fusion. The agreement includes upfront, milestone payments, and a perpetual royalty framework, aiming to expand ATEC's presence in the regenerative spine market. Concurrently, Theradaptive initiated a Series B financing round to further develop its protein-engineering platform.
Does Alphatec (ATEC) Pairing With OsteoAdapt Quietly Redraw Its Spine Biologics Investment Narrative?
Alphatec Holdings, Inc. has partnered with Theradaptive, Inc. for exclusive U.S. commercialization rights to the OsteoAdapt osteoinductive bone graft, alongside strong preliminary 2025 results and a 2026 revenue guidance of US$890 million. While the partnership introduces a high-potential biologic, Alphatec's near-term growth remains tied to its existing core hardware, navigation, and robotics, with the new biologic still in clinical trials and awaiting FDA approval. The company's investment narrative continues to depend on translating surgeon adoption and innovation into durable revenue growth within a competitive spine care market.
ATEC and Theradaptive Enter Strategic Partnership for Breakthrough Regenerative Technology in Spinal Fusion
Alphatec Holdings, Inc. (ATEC) and Theradaptive, Inc. announced a strategic partnership for ATEC to exclusively market and distribute Theradaptive’s OsteoAdapt® osteoinductive bone graft for spinal fusion in the U.S. This collaboration aims to revolutionize spine surgery with Theradaptive's proprietary AMP2™ protein technology, which has received three FDA Breakthrough Device Designations. Theradaptive has also initiated a Series B investment round to fund clinical studies and scale its technology platform in conjunction with the ATEC partnership.
Director’s Massive Share Sale Creates Stir at Alphatec Holdings
A significant sale of 250,000 shares, valued at nearly $5M, by Director David R Pelizzon at Alphatec Holdings (ATEC) has caused concern and a -17.97% drop in stock price. This transaction raises questions about leadership confidence and internal projections, especially given the company's mixed financial performance with strong revenue but negative profitability and high debt. Investors are now closely watching for further strategic announcements from Alphatec to understand the context and potential implications of this sale.
At US$22.65, Is Alphatec Holdings, Inc. (NASDAQ:ATEC) Worth Looking At Closely?
Alphatec Holdings, Inc. (NASDAQ:ATEC) has seen a significant price jump recently, trading near its 52-week high at US$22.65. While analysts expect strong profit growth of 86% over the next couple of years, Simply Wall St's intrinsic value calculation suggests the stock is currently overvalued by 30% at $17.43. Investors are advised that the buying opportunity may have passed, and potential investors should consider other factors due to the stock's volatility and current overvaluation.
Alphatec stock tumbles after disappointing 2026 guidance
Alphatec Holdings (NASDAQ:ATEC) stock dropped 21% after its 2026 revenue growth guidance of 17% disappointed investors, despite exceeding analyst consensus. The spine-focused medical device company reported preliminary 2025 revenues that slightly beat expectations and maintained its 2025 adjusted EBITDA forecast. Alphatec also announced the acquisition of U.S. distribution rights for Theradaptive’s OsteoAdapt.
ATEC Announces Select Preliminary Financial Results for 2025 and Provides 2026 Outlook
Alphatec Holdings, Inc. (ATEC) announced strong preliminary financial results for full-year 2025, with total revenue growing 25% to approximately $764 million, driven by surgeon adoption and increased surgical volume. The company also provided a positive outlook for 2026, anticipating $890 million in total revenue and $130 million in adjusted EBITDA. Additionally, ATEC acquired exclusive U.S. distribution rights for Theradaptive’s OsteoAdapt®, a next-generation rhBMP-2 biologic currently in Phase II clinical trials for spinal fusion.
Alphatec Holdings, Inc. Announces Preliminary 2025 Financial Results and 2026 Outlook
Alphatec Holdings, Inc. has released its preliminary financial results for full-year 2025, reporting total revenue growth of 25% to $764 million and reaffirming its adjusted EBITDA guidance of $91 million. The company also provided a strong 2026 outlook, projecting total revenue of $890 million and adjusted EBITDA of $130 million, fueled by surgeon adoption and strategic acquisitions like Theradaptive’s OsteoAdapt®. Management expressed confidence in their procedural ecosystem strategy and clinical advancements driving industry-leading results.
Theradaptive, Inc. announced that it expects to receive funding from Alphatec Holdings, Inc.
Theradaptive, Inc. has secured a round of funding on January 12, 2026, with new investor Alphatec Holdings, Inc. participating in the transaction. The funding involves the issuance of convertible preferred stock by Theradaptive.
Alphatec Holdings stock hits 52-week high at 22.66 USD
Alphatec Holdings Inc. (ATEC) stock reached a 52-week high of $22.66, reflecting a 1-year return of 127.43% and strong investor confidence despite the company not being profitable in the last twelve months. The surge is supported by robust revenue growth of 27.11% and impressive third-quarter earnings that exceeded market expectations, leading analysts to maintain strong buy ratings and raise price targets. However, InvestingPro analysis suggests the stock may be significantly overvalued compared to its Fair Value.
Alphatec Holdings stock hits 52-week high at 22.66 USD By Investing.com
Alphatec Holdings (ATEC) recently reached a 52-week high of $22.66 per share, reflecting a strong year with a 127.43% return despite the company not being profitable in the last twelve months. The stock's positive momentum is also supported by strong third-quarter earnings that exceeded expectations, leading several analysts to raise their price targets and maintain "Buy" ratings. However, InvestingPro analysis suggests the stock might be significantly overvalued compared to its Fair Value.
Alphatec Holdings (NASDAQ:ATEC) rallies 7.8% this week, taking one-year gains to 135%
Alphatec Holdings (NASDAQ:ATEC) surged 7.8% this week, bringing its one-year gains to an impressive 135%. Despite not being profitable in the past year, the company demonstrated strong revenue growth of 27%, which outpaced its stock performance. Analysts' consensus estimates suggest a positive outlook for future profits, making it an interesting stock to watch.
Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Average Rating of "Moderate Buy" from Analysts
Alphatec Holdings, Inc. (NASDAQ:ATEC) has an average "Moderate Buy" rating from analysts, with a 12-month average target price of $22.82. Despite beating earnings estimates last quarter with $0.03 EPS and $196.5 million in revenue, the company remains unprofitable. There has been significant insider selling, though insiders still own 20.9% of the stock and institutions hold 66.35%.
Alphatec Holdings stock hits 52-week high at 22.66 USD By Investing.com
Alphatec Holdings Inc. (ATEC) recently reached a 52-week high of $22.66, marking a robust year with a 127.43% return despite not being profitable in the past twelve months. The company's revenue grew by 27.11%, and it achieved an 89.4% price return over the last six months. This surge in stock price follows strong third-quarter earnings that exceeded market expectations, leading several analysts to maintain "Buy" or "Overweight" ratings and increase price targets.
Barclays Raises Price Target for Alphatec Holdings (ATEC) to $27
Barclays has increased its price target for Alphatec Holdings (ATEC) to $27 from $23, while maintaining an "Overweight" rating, citing continued optimism for the company's stock. This new target represents a 17.39% increase from the previous one. Alphatec Holdings is a medical technology company specializing in surgical treatments for spinal disorders.
Are Alphatec Holdings, Inc. (NASDAQ:ATEC) Investors Paying Above The Intrinsic Value?
Alphatec Holdings (NASDAQ:ATEC) appears to be overvalued by approximately 22%, with an estimated fair value of US$17.32 based on a 2-Stage Free Cash Flow to Equity model, while its current share price is US$21.20. This fair value estimate is also 30% lower than the analyst price target of US$24.62. The analysis highlights that, despite forecasted reduced losses and sufficient cash runway, the company's valuation based on its discounted future cash flows suggests it is currently trading above its intrinsic worth.
Are Alphatec Holdings, Inc. (NASDAQ:ATEC) Investors Paying Above The Intrinsic Value?
Alphatec Holdings, Inc. (NASDAQ: ATEC) has an estimated fair value of US$17.32 based on a 2-Stage Free Cash Flow to Equity model. Its current share price of US$21.20 suggests it might be 22% overvalued, and this fair value estimate is 30% lower than the analyst price target of US$24.62. Investors should consider that the Discounted Cash Flow model provides an approximate valuation and should be used in conjunction with other metrics and assumptions to evaluate the company's potential.
Trading the Move, Not the Narrative: (ATEC) Edition
This article analyzes Alphatec Holdings Inc. (NASDAQ: ATEC) using AI-driven models, revealing a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional risk-reward short setup and provides distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for various risk profiles. The analysis points to a mid-channel oscillation pattern and prevailing positive sentiment.
